Abnormal fucosylation of alpha-fetoprotein in patients with nonalcoholic steatohepatitis.
alpha-fetoprotein
diabetes mellitus
nonalcoholic steatohepatitis
Journal
Hepatology research : the official journal of the Japan Society of Hepatology
ISSN: 1386-6346
Titre abrégé: Hepatol Res
Pays: Netherlands
ID NLM: 9711801
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
revised:
03
02
2021
received:
31
12
2020
accepted:
08
02
2021
pubmed:
18
2
2021
medline:
18
2
2021
entrez:
17
2
2021
Statut:
ppublish
Résumé
Nonalcoholic steatohepatitis (NASH) is a risk factor for nonvirus-related hepatocellular carcinoma, which is increasing in prevalence. The aim of this study was to clarify the clinical application of fucosylated alpha-fetoprotein (AFP-L3) in the process of nonalcoholic fatty liver (NAFL) disease development. Serum samples from 115 diabetes mellitus (DM), 36 NAFL, and 119 NASH patients were analyzed for AFP-L3 expression using raw data of a micro total analysis system. These data were then compared with the clinical characteristics of the patients. A validation study was also undertaken with 55 samples (17 NAFL and 38 NASH). Trace amounts of AFP-L3 were detected in 3.5%, 16.7%, and 58.0% of patients with DM, NAFL, and NASH, respectively. The odds ratio of AFP-L3 positivity for the diagnosis of NASH in multivariate analysis was 9.81 (95% confidence interval, 3.77-25.5). The rates in patients without fibrosis or with stage 1, stage 2, stage 3, and stage 4 fibrosis were 14.7%, 31.3%, 63.0%, 86.2%, and 100%, respectively. The rates were significantly increased according to the advancement of liver fibrosis (p < 0.001); however, no difference in the positive rate of AFP-L3 was observed between patients with and without fatty livers and between patients with normal and abnormal transaminase. The same relationship was also observed in the validation cohort. Abnormal fucosylation of AFP occurred in patients with NASH, so it could be useful for the screening of NASH in patients with DM, as well as for the differential diagnosis of NASH and the evaluation of fibrosis.
Types de publication
Journal Article
Langues
eng
Pagination
548-553Informations de copyright
© 2021 The Japan Society of Hepatology.
Références
Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003-2012. J Am Med Assoc. 2015;313:1973-4.
Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-31.
Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2:901-10.
Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69:2672-82.
Dohi C, Nouso K, Miyahara K, Morimoto Y, Wada N, Kinugasa H, et al. Potential of alpha-fetoprotein as a prognostic marker after curative radiofrequency ablation of hepatocellular carcinoma. Hepatol Res. 2016;46:916-23.
Trevisani F, Garuti F, Neri A. Alpha-fetoprotein for diagnosis, prognosis, and transplant selection. Semin Liver Dis. 2019;39:163-77.
Izumi N, Asahina Y, Kurosaki M, Yamada G, Kawai T, Kajiwara E, et al. Inhibition of hepatocellular carcinoma by PegIFNalpha-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study. J Gastroenterol. 2013;48:382-90.
Oze T, Hiramatsu N, Yakushijin T, Miyazaki M, Yamada A, Oshita M, et al. Post-treatment levels of alpha-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy. Clin Gastroenterol Hepatol. 2014;12:1186-95.
Takeuchi Y, Ikeda F, Osawa T, Araki Y, Takaguchi K, Morimoto Y, et al. Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development. World J Hepatol. 2015;7:2220-8.
Miyoshi E, Kamada Y, Suzuki T. Functional glycomics: application to medical science and hepatology. Hepatol Res. 2020;50:153-64.
Suzuki Y, Aoyagi Y, Muramatsu M, Sekine C, Isemura M, Ichida F. Close topographical relationship in alpha foetoprotein (AFP) between a Lens culinaris binding glycan and the epitope recognized by AFP-reactive monoclonal antibody, 18H4. Br J Cancer. 1987;55:147-52.
Taketa K, Izumi M, Ichikawa E. Distinct molecular species of human alpha-fetoprotein due to differential affinities to lectins. Ann N Y Acad Sci. 1983;417:61-8.
Toyoda H, Kumada T, Tada T, Sone Y, Kaneoka Y, Maeda A. Tumor markers for hepatocellular carcinoma: simple and significant predictors of outcome in patients with HCC. Liver Cancer. 2015;4:126-36.
Nouso K, Kobayashi Y, Nakamura S, Kobayashi S, Takayama H, Toshimori J, et al. Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein. J Gastroenterol Hepatol. 2011;26:1195-200.
Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, et al. High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma. J Gastroenterol. 2014;49:555-63.
Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413-9.
Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467-74.
Kagebayashi C, Yamaguchi I, Akinaga A, Kitano H, Yokoyama K, Satomura M, et al. Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis. Anal Biochem. 2009;388:306-11.
Uozumi N, Yanagidani S, Miyoshi E, Ihara Y, Sakuma T, Gao CX, et al. Purification and cDNA cloning of porcine brain GDP-L-Fuc:N-acetyl-beta-D-glucosaminide alpha1>6fucosyltransferase. J Biol Chem. 1996;271:27810-7.
Yanagidani S, Uozumi N, Ihara Y, Miyoshi E, Yamaguchi N, Taniguchi N. Purification and cDNA cloning of GDP-L-Fuc:N-acetyl-beta-D-glucosaminide:alpha1-6 fucosyltransferase (alpha1-6 FucT) from human gastric cancer MKN45 cells. J Biochem. 1997;121:626-32.
Noda K, Miyoshi E, Uozumi N, Yanagidani S, Ikeda Y, Gao C, et al. Gene expression of alpha1-6 fucosyltransferase in human hepatoma tissues: a possible implication for increased fucosylation of alpha-fetoprotein. Hepatology. 1998;28:944-52.
Nakagawa T, Moriwaki K, Terao N, Nakagawa T, Miyamoto Y, Kumada Y, et al. Analysis of polarized secretion of fucosylated alpha-fetoprotein in HepG2 cells. J Proteome Res. 2012;11:2798-806.
Nakagawa T, Uozumi N, Nakano M, Mizuno-Horikawa Y, Okuyama N, Taguchi T, et al. Fucosylation of N-glycans regulates the secretion of hepatic glycoproteins into bile ducts. J Biol Chem. 2006;281:29797-806.
Abe M, Miyake T, Kuno A, Imai Y, Sawai Y, Hino K, et al. Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol. 2015;50:776-84.
Kamada Y, Akita M, Takeda Y, Yamada S, Fujii H, Sawai Y, et al. Serum fucosylated haptoglobin as a novel diagnostic biomarker for predicting hepatocyte ballooning and nonalcoholic steatohepatitis. PloS One. 2013;8:e66328.
Yamasaki Y, Nouso K, Miyahara K, Wada N, Dohi C, Morimoto Y, et al. Use of non-invasive serum glycan markers to distinguish non-alcoholic steatohepatitis from simple steatosis. J Gastroenterol Hepatol. 2015;30:528-34.
Kobayashi T, Ogawa K, Furukawa JI, Hanamatsu H, Hato M, Yoshinaga T, et al. Quantifying protein-specific N-glycome profiles by focused protein and immunoprecipitation glycomics. J Proteome Res. 2019;18:3133-41.